Caris Life Sciences Inc (CAI) Stock Analysis
Verdict: WATCH (do not buy)
Steep valuation at 75.85x P/E and price above $26.00 consensus cap near-term gains despite 38.5% top-line growth and $797.8M cash balance.
Investment score: 55/100
Analysis as of
Is Caris Life Sciences Inc stock worth reviewing? AI model thesis
Caris Life Sciences exhibits robust commercial traction (+38.5% revenue growth) and healthy liquidity ($797.8M cash), but a rich valuation of 75.85x P/E and a market price 8.5% above analyst consensus ($26.00) suggest near-term upside is capped.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Caris Life Sciences Inc opportunities and risks
What speaks for CAI
- Commercial Scaling in Molecular Diagnostics
What speaks against CAI
- Elevated Valuation Premium vs Peers and Consensus Target
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CAI | 75.9x | 8.1x | 44.8x | 69.7% | 10.6% | 1.8% |
| TGTX | 18.3x | 10.7x | 65.8x | 82.4% | 55.2% | -0.0% |
| IBRX | n/a | 50.0x | n/a | 94.6% | -598.6% | -4.4% |
| SYRE | n/a | 87.5x | n/a | 0.0% | -197.7% | -2.6% |
| IMVT | n/a | 1058.3x | n/a | 97.1% | -7585.9% | -5.5% |
| IONS | n/a | 8.5x | 2.2x | 98.2% | -64.6% | -7.5% |
| Peer median | n/a | 50.0x | n/a | 94.6% | -197.7% | -4.4% |
Frequently asked questions about Caris Life Sciences Inc (CAI)
Is CAI stock a good investment?
The cached TradeMates AI model rates Caris Life Sciences Inc as WATCH (do not buy) with an investment score of 55/100. Caris Life Sciences exhibits robust commercial traction (+38.5% revenue growth) and healthy liquidity ($797.8M cash), but a rich valuation of 75.85x P/E and a market price 8.5% above analyst consensus ($26.00) suggest near-term upside is capped. This is algorithmic model output, not personal investment advice.
Is CAI stock a buy?
The TradeMates model verdict for CAI is WATCH (do not buy) with an investment score of 55/100. Treat this as a model signal to review, not a personal buy recommendation.